Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Reoperative coronary artery bypass procedures: risk factors for early mortality and late survival.Eur J Cardiothorac Surg. 1997; 11: 129-133
- Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery.Circulation. 1997; 95: 868-877
- One-year clinical outcomes of protected and unprotected left main coronary artery stenting.Eur Heart J. 2003; 24: 1554-1559
- Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients.Circulation. 2001; 104: 1609-1614
- A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease.Am Heart J. 2008; 155: 274-283
- Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry.Heart. 2007; 93: 1251-1255
- Outcomes and complications associated with off-label and untested use of drug-eluting stents.JAMA. 2007; 297: 1992-2000
- Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry.Circulation. 2006; 114: 2154-2162
- Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis.JACC Cardiovasc Interv. 2010; 3: 602-611
- Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry.J Am Coll Cardiol. 2007; 50: 2029-2036
- Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries.J Am Coll Cardiol. 2006; 47: 1530-1537
The study was funded by Cordis Corporation, Miami, Florida, the manufacturer of the Cypher stent. Dr. Kip and Dr. Williams have received research support from Cordis Corporation.